Patents by Inventor Omid Veiseh

Omid Veiseh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240207508
    Abstract: A bioelectronic implantable device includes engineered cells and an electronically controlled stimulator that regulates a quantity and timing of therapeutic agent produced by the engineered cells.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Inventors: Jonathan Rivnay, Omid Veiseh, Jacob Robinson, Samantha T. Fleury, Matthew C. Parker, Fatima T. Alrashdan
  • Publication number: 20240189505
    Abstract: A bioelectronic wearable device includes engineered cells and an electronically controlled stimulator that regulates a quantity and timing of therapeutic agent produced by the engineered cells.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 13, 2024
    Inventors: Jonathan Rivnay, Omid Veiseh, Jacob Robinson
  • Publication number: 20240189458
    Abstract: The present disclosure provides compositions comprising encapsulated engineered bacteria. The bacteria may be engineered to act as sensors of biomarkers, such as inflammation, as well as to produce diagnostic or therapeutic agents.
    Type: Application
    Filed: June 15, 2022
    Publication date: June 13, 2024
    Applicants: William Marsh Rice University, Baylor College of Medicine
    Inventors: Jeffrey TABOR, Omid VEISEH, Robert BRITTON, Moshe BARUCH, Annie GOODWIN, Elena MUSTEATA, Michael DOERFERT, Samira AGHLARA-FOTOVAT, Maxwell HUNT
  • Patent number: 11945786
    Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 2, 2024
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Omid Veiseh, Richard Heidebrecht, Paul Kevin Wotton, Matthias Alexander Oberli, Robert James Miller
  • Publication number: 20240041939
    Abstract: The present disclosure relates to implantable constructs (encapsulated cells) designed to deliver therapeutic reagents, such as IL-12 and/or IL-12 and methods of using the same to treat conditions, such as cancer.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 8, 2024
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Samira AGHLARA-FOTOVAT
  • Publication number: 20240041755
    Abstract: The present disclosure relates to implantable constructs and related compositions comprising a plurality of cells producing antigens and/or immune effector molecules.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 8, 2024
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Boram KIM, Damon BERMAN, Lauren CHENG, David ZHANG
  • Publication number: 20230265149
    Abstract: The present disclosure relates to implantable constructs (encapsulated cells) designed to deliver antigenic therapeutic reagents, such as IL-2.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 24, 2023
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, David ZHANG, Sudip MUKHERJEE, Maria RUOCCO, Michael DOERFERT, Amanda NASH, Samira AGHLARA-FOTOVAT
  • Publication number: 20230210908
    Abstract: The present disclosure provides expression constructs designed to provide for expression of therapeutic proteins from engineered cells. The engineered cells may be encapsulated into implantable elements that allow for the therapeutic protein to be released into from the capsule while protecting the cell from the immune system of a patient into which the capsule is implanted.
    Type: Application
    Filed: February 11, 2021
    Publication date: July 6, 2023
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Bhagyashree Kishor BACHHAV, Carlos Alberto ORIGEL MARMOLEJO, Damon BERMAN, Christian SCHREIB, Laura SEGATORI, Alen TRUBELJA, Oleg A. IGOSHIN, Andrew D. HECHT
  • Publication number: 20230123802
    Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 20, 2023
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
  • Publication number: 20230054899
    Abstract: Provided herein are high-throughput methods for genetic barcoding and analysis, e.g., for tagging each biomaterial apsule with a barcode cell. These barcode cells are derived from patient samples, and thus embody natural human genetic variation. Also provided are SNP panels that can be used as genetic barcodes to identify the identity of a cell.
    Type: Application
    Filed: January 14, 2021
    Publication date: February 23, 2023
    Applicant: William Marsh Rice University
    Inventors: David Yu ZHANG, Ping SONG, Omid VEISEH, Siavash PARKHIDEH, Sudip MUKHERJEE, Maria Isabel RUOCCO, Boram KIM, Yuxuan CHENG
  • Publication number: 20220411795
    Abstract: The present disclosure provides expression constructs designed to provide for stable and/or inducible, tightly controlled production of genetically encoded payloads from engineered cells. These cassettes allow cells to be engineered to express genetically encoded payloads despite epigenetic silencing. As such, provided herein are expression systems for use in methods to engineer cells using CRISPR dCas9-activator systems such that expression of genetically encoded payloads (e.g., therapeutic proteins) can be optimized to overcome epigenetic silencing. In addition, provided herein are engineered cells comprising the expression systems.
    Type: Application
    Filed: October 30, 2020
    Publication date: December 29, 2022
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Isaac HILTON, Jing LI, Maria Isabel JARVIS RUOCCO, Christian Cody SCHREIB
  • Publication number: 20220313599
    Abstract: The present disclosure relates to implantable constructs designed to deliver antigenic therapeutic reagents to a subject while providing protection from host immune responses. In certain aspects, the constructs are designed to degrade over time or upon a particular signal, thereby providing control of the length of time the therapeutic agent is delivered to the subject.
    Type: Application
    Filed: August 7, 2020
    Publication date: October 6, 2022
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Amanda NASH, Maria Isabel JARVIS-RUOCCO, Sudip MUKHERJEE, Michael David DOERFERT, Samira AGHLARA-FOTOVAT, David Yu ZHANG
  • Patent number: 11446239
    Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: September 20, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
  • Publication number: 20220267794
    Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 25, 2022
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Jeffrey Charles Way, Paul Kevin Wotton, Zoe Yin, Elina Makino, Brian Richard Fluharty, Marianthi Papakosta
  • Publication number: 20220143270
    Abstract: The disclosure describes new devices and methods for vascularizing devices and methods for implanted diagnostics and therapeutics. The present disclosure provides, in certain embodiments, a device containing a degradable shell and a non-degradable core. In certain embodiments, the non-degradable core can include encapsulated therapeutic cells and/or biosensors, wherein the degradable shell serves as a scaffold for blood vessel growth, resulting in enhanced blood flow to the cells and/or biosensors.
    Type: Application
    Filed: February 17, 2020
    Publication date: May 12, 2022
    Applicant: William Marsh Rice University
    Inventors: Omid VEISEH, Bagrat GRIGORYAN, Daniel Warren SAZER, Siavash PARKHIDEH, Jordan MILLER, Sudip MUKHERJEE
  • Patent number: 11318231
    Abstract: Neurological implants whose surfaces have been chemically and covalently modified to impart beneficial properties to the neurological implants are described. The neurological implants possess improved biocompatibility compared to a corresponding neurological implant that lacks the chemical modification. Following implantation in a subject, the surface-modified neurological implants induce a lower-foreign body response, compared to a corresponding unmodified product.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 3, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, SEATTLE CHILDREN'S HOSPITAL
    Inventors: Omid Veiseh, Robert S. Langer, Daniel G. Anderson, William Shain, Brian W. Hanak, Samuel R. Browd, Robert F. Hevner
  • Patent number: 11307197
    Abstract: Polyarginine-coated nanoparticle, and methods for making and using the nanoparticle. The nanoparticle can have a core that includes a material that imparts magnetic resonance imaging activity to the particle and, optionally, include one or more of an associated therapeutic agent, targeting agent, and diagnostic agent.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: April 19, 2022
    Assignee: University of Washington
    Inventors: Miqin Zhang, Omid Veiseh, Chen Fang, Forrest Kievit
  • Patent number: 11266606
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: March 8, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20220042100
    Abstract: Provided herein are methods for quantifying foreign cell-free DNA (cfDNA) via SNP profiling of low-volume blood sample. The methods allow for monitoring the status of organ transplant rejection through analysis of small volumes of patient capillary blood samples collected non-invasively with fingersticks or other devices. The methods also allow for guiding the dosage of immunosuppressant and for preparing for a new organ transplant in case of imminent organ failure.
    Type: Application
    Filed: December 5, 2019
    Publication date: February 10, 2022
    Inventors: David Yu ZHANG, Xi CHEN, Omid VEISEH, Peng DAI, Kerou ZHANG
  • Publication number: 20220031913
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: July 15, 2021
    Publication date: February 3, 2022
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson